BioClonetics is a biotechnology company engaged in the discovery, acquisition and development of proprietary pharmaceutical compounds and new technologies for use in the diagnosis and treatment of HIV/AIDS and other infectious diseases.

BioClonetics has created a human cell line that produces a human antibody (designated as CLONE 3) that neutralizes HIV, the virus that causes AIDS.  As its primary mission, the Company is preparing for animal and human trials to ready its antibody for use in treating those with HIV/AIDS and for production of an AIDS vaccine.

Development of CLONE 3 for use as a therapy and vaccine against HIV is being carried out in conjunction with the University of Texas Southwestern Medical Center, Dallas, Texas.  Use of CLONE 3 in pediatrics protocols and research will be conducted at the David Geffen School of Medicine at University of California at Los Angeles, California.

The Company also has created human cell lines that produce human antibodies against other infectious diseases, including rabies, influenza, tetanus and diphtheria.  As its secondary mission, the Company is testing these antibodies to prepare them for use as therapies and vaccines against these diseases.